FDA Clearance Tracker · P000039-S050
AMPLATZER SEPTAL DEFECT OCCLUDER
Last checked: Nov 20, 2026Latest source record: Aug 14, 2015 (this decision)Source: openFDAMethods & limitations
Decided
Aug 14, 2015
Approved
Time to decision
154 days
Received Mar 13, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P000039-S050
- Device name
- AMPLATZER SEPTAL DEFECT OCCLUDER
- Applicant
- ABBOTT MEDICAL
- Applicant location
- St. Paul, MN
- Received
- Mar 13, 2015
- Decided
- Aug 14, 2015
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P000039
Device type
- Device type
- OCCLUDER, PATENT DUCTUS, ARTERIOSUS (MAE)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR MANUFACTURING SITES LOCATED AT ST. JUDE MEDICAL, COST RICA LTDA.
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.